YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Wall Street New York stock exchange stock market] alexsl Several sub-$10 stocks are flashing elevated momentum signals, with a handful already entering traditionally overbought territory as recent rallies push their Relative Strength Inde…
RenovoRx, Inc. MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®…
RenovoRx, Inc. MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®,…
Key Points Interested in RenovoRx, Inc.? Here are five stocks we like better. Record commercial growth: Second-quarter revenue rose 115% year over year to $909,000, supported by increased RenovoCath procedures, repeat orders and expansion…
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Managing Director of KCSA Strategic Communications - Valter Pinto Chief Executive Officer - Shaun Bagai Chief Medical Officer executive chair an…
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items…
(RTTNews) - Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, announced the appointment of James Ahlers as Chief Financial Officer (CFO), effective immediately. Ahlers…
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago. These figures are adjusted for non-recurring…
MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.(“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of the…
(RTTNews) - RenovoRx, Inc. (RNXT), a life sciences company, announced Thursday that the U.S. Food and Drug Administration (FDA) recently granted Orphan Drug Designation (ODD) for oxaliplatin for the treatment of pancreatic cancer. Oxalipla…
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects MOUNTA…
Image source: The Motley Fool. DATE Thursday, May 14, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Shaun R. BagaiChief Medical Officer and Executive Chair — Ramtin Agah, M.D.Chief Financial Officer — Mark Voll TAKEAWAY…
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it…
Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago. These figures are adjusted for non-recurring items. This quarterly repo…
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer Metabolic Imaging, Used to Evaluate Therapeutic Outcome Following Tre…
RenovoRx, Inc. RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing…
MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, F…
(RTTNews) - RenovoRx, Inc. (RNXT), a life-sciences company, announced financial results for the full year 2025, reflecting a wider net loss despite revenue growth. In addition, the firm provided a business update. Following the news in the…
The following companies are expected to report earnings after hours on 03/30/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Progress Software Corporation (PRGS)is reporting for the quarter ending February…
* RenovoRx (RNXT [https://seekingalpha.com/symbol/RNXT]) announced on Wednesday the execution of definitive securities purchase agreements with institutional investors for an oversubscribed common stock and milestone warrant private placem…
Bolstered Cash Position Expected to Capitalize the Company’s Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data Oversubscribed Financing Led by Leading Life Science Institutional Investors with Participati…
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to…
(RTTNews) - Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations. ALX Oncology Holdings Inc. (ALXO) surg…
(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% to…
(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura Oncology, Inc. (KURA) led the group with…
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FD…
As the U.S. stock market experiences a mixed performance with major indices like the Nasdaq Composite and S&P 500 inching closer to record highs, investors are keenly observing economic indicators such as inflation data that could influenc…
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-c…
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-c…
As the U.S. stock market experiences a downturn with the S&P 500 closing lower for four consecutive sessions and tech stocks under pressure, investors are keenly observing key earnings reports and economic indicators that could impact futu…
(RTTNews) - The after-hours session on Friday, November 14, 2025, brought notable moves across several biotech and therapeutics names, as corporate updates, financial results, and strategic announcements drove sharp price reactions. From a…
* RenovoRx press release [https://seekingalpha.com/pr/20307315-renovorx-reports-third-quarter-2025-financial-results-including-approximately-900000-in-year] (RNXT [https://seekingalpha.com/symbol/RNXT]): Q3 GAAP EPS of -$0.08 in-line. * Re…
September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) --…
As the U.S. market experiences a surge in optimism following news of a potential deal to end the government shutdown, major indexes like the Nasdaq and S&P 500 have rebounded significantly, reflecting renewed investor confidence. In such d…
The U.S. stock market has recently seen major indices like the Dow Jones, S&P 500, and Nasdaq reach new highs, driven by optimism surrounding U.S.-China trade talks and the potential for Federal Reserve interest rate cuts. In this environm…